Conference Call Wednesday, October 28th, at 11:00 A.M.

RALEIGH, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) — Highwoods Properties, Inc. (NYSE:HIW) will release its third quarter 2026 results on Tuesday, October 27th, after the market closes.

A conference call will be held the next day, Wednesday, October 28th, at 11:00 A.M. Eastern time.

For US/Canada callers, dial (833) 461-5787 and enter meeting ID 767718045. International callers should dial (585) 542-9983 and enter the same meeting ID. A live, listen-only webcast can be accessed on the Company’s website at www.highwoods.com through the “Highwoods Properties Q3 2026 Earnings Call” link under the “Investors” section. A replay of the call will also be available on the Company’s website.

About Highwoods
Highwoods Properties, Inc., headquartered in Raleigh, is a publicly-traded (NYSE:HIW), fully-integrated office real estate investment trust (“REIT”) that owns, develops, acquires, leases and manages properties primarily in the best business districts (BBDs) of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh and Tampa. Our vision is to be a leader in the evolution of commercial real estate for the benefit of our customers, our communities and those who invest with us. Our mission is to create environments and experiences that inspire our teammates and our customers to achieve more together. We are in the work-placemaking business and believe that by creating exceptional environments and experiences, we can deliver greater value to our customers, their teammates and, in turn, our shareholders. For more information about Highwoods, please visit our website at www.highwoods.com.

Contact: Brendan Maiorana                                        
Executive Vice President and Chief Financial Officer
brendan.maiorana@highwoods.com 
919-872-4924

Top 10 Airlines Based on Total Ancillary Revenue

SeatMaps.com, IdeaWorks
SeatMaps.com, IdeaWorks

San Antonio, TX, Sept. 15, 2026 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (“the Company”), a registered investment advisory firm[1] with expertise in gold mining stocks and the airline industry, is pleased to announce that it will continue its payment of monthly dividends.

The Company’s Board of Directors (the “Board”) approved payment of the $0.0075 per share per month dividend beginning in October 2026 and continuing through December 2026. The record dates are October 12, November 16 and December 14, and the payment dates will be October 26, November 30 and December 28.

Based on the September 11, 2026, closing price of $2.91 this monthly dividend represents an annualized yield of approximately 3.1%.

Travelers Are Spending More Per Trip

The Company notes that across the travel economy, revenue is growing considerably faster than passenger and guest counts, a pattern that points to improving pricing power rather than simple volume recovery. U.S. travel spending reached $122.8 billion in July, running 5.8% ahead of the same month last year, even as air passenger volume an overseas arrivals came in below year-ago level.[2]

The airline data makes the point most clearly. Across 58 carriers, 2025 revenue grew 7.2% on a passenger traffic increase of just 2.5%, driven by higher average fares and a $13.2 billion jump in ancillary revenue, a 13.4% gain. Thirty airlines now book more than a billion dollars annually in ancillary sales, up from 27 the prior year, according to IdeaWorks.[3]

Hotels show the same signature, with revenue per available room climbing 8.2% nationally on room demand growth of 2.8%, and urban properties posting an 8.2% gain of their own at 14.8%.

At the high end, luxury travel bookings for this fall rose 59% while sales rose 69%, with September sales up 77% as affluent travelers move their trips out of the summer crowds.[4]

“We’ve said for years that travel has shifted from a cyclical business to a secular growth story, and the current numbers support that,” said Frank Holmes, Chief Executive Officer and Chief Investment Officer of U.S. Global Investors. “Carriers and hotel operators are earning more from every customer who walks through the door. That is a healthier and more durable form of growth than filling more seats at the same fare, and it tends to show up in margins before it shows up in headlines.”

The Company follows these trends through its specialized funds and its Smart Beta 2.0 quant investment strategy for thematic products. Its U.S. Global Jets ETF (NYSE: JETS) provides investors access to the global airline industry, including airline operators, manufacturers and online travel agencies.

About U.S. Global Investors, Inc.
The story of U.S. Global Investors goes back more than 50 years when it began as an investment club. Today, U.S. Global Investors, Inc. (www.usfunds.com) is a registered investment adviser that focuses on niche markets around the world. Headquartered in San Antonio, Texas, the Company provides investment advisory and other services to U.S. Global Investors Funds and U.S. Global ETFs.

# # #

Please consider carefully a fund’s investment objectives, risks, charges and expenses. For this and other important information, obtain a statutory and summary prospectus for JETS here. Read it carefully before investing.

Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the funds. Brokerage commissions will reduce returns.

Because the funds concentrate their investments in specific industries, the funds may be subject to greater risks and fluctuations than a portfolio representing a broader range of industries. The funds are non-diversified, meaning they may concentrate more of their assets in a smaller number of issuers than diversified funds. The funds invest in foreign securities which involve greater volatility and political, economic and currency risks and differences in accounting methods. These risks are greater for investments in emerging markets. The funds may invest in the securities of smaller-capitalization companies, which may be more volatile than funds that invest in larger, more established companies.

The performance of the funds may diverge from that of the index. Because the funds may employ a representative sampling strategy and may also invest in securities that are not included in the index, the funds may experience tracking error to a greater extent than funds that seek to replicate an index. The funds are not actively managed and may be affected by a general decline in market segments related to the index.

Airline Companies may be adversely affected by a downturn in economic conditions that can result in decreased demand for air travel and may also be significantly affected by changes in fuel prices, labor relations and insurance costs.

Foreign and emerging market investing involves special risks such as currency fluctuation and less public disclosure, as well as economic and political risk. By investing in a specific geographic region, such as China and/or Taiwan, a regional ETFs returns and share price may be more volatile than those of a less concentrated portfolio.

Cargo Companies may be adversely affected by downturn in economic conditions that can result in decreased demand for sea shipping and freight. All opinions expressed and data provided are subject to change without notice. Some of these opinions may not be appropriate to every investor.

This news release may include certain “forward-looking statements” including statements relating to revenues, expenses, and expectations regarding market conditions. These statements involve certain risks and uncertainties. There can be no assurance that such statements will prove accurate and actual results and future events could differ materially from those anticipated in such statements.

The continuation of future cash dividends will be determined by U.S. Global Investors’ Board of Directors, at its sole discretion, after review of the Company’s financial performance and other factors, and is dependent on earnings, operations, capital requirements, general financial condition of the Company, and general business conditions.

Holdings may change daily. Holdings are reported as of the most recent quarter-end. The following securities mentioned in the press release were held by one or more accounts managed by U.S. Global Investors as of (6/30/2026): United Airlines Holdings Inc., Delta Air Lines Inc., American Airlines Group Inc., Southwest Airlines Co., Ryanair Holdings PLC, easyJet PLC, International Consolidated Airlines Group S.A., Deutsche Lufthansa AG, Air France-KLM, Alaska Air Group Inc.

Smart Beta 2.0 is an investment approach that blends the low cost and transparency of passive index tracking with the performance-seeking goals of active management.

All opinions expressed and data provided are subject to change without notice. Some of these opinions may not be appropriate to every investor.


[1] Registration does not imply a certain level of skill or training.
[2] U.S. Travel Association, “Travel Insights Dashboard,” 2 September 2026. https://www.ustravel.org/research/travel-recovery-insights-dashboard
[3] IdeaWorksCompany, “2026 SeatMaps.com Yearbook of Ancillary Revenue,” 8 September 2026. https://ideaworkscompany.com/2026-seatmaps-com-yearbook-of-ancillary-revenue-by-ideaworkscompany-report/
[4] Whitten, Sarah. CNBC, 4 September 2026. https://www.cnbc.com/2026/09/04/fall-travel-wealthy-europe.html

Attachment

CONTACT: Holly Schoenfeldt
U.S. Global Investors, Inc.
210.308.1268
hschoenfeldt@usfunds.com

HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted at an exercise price of $31.44 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to continued employment with vTv on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) — The Board of Directors of TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, declared a quarterly dividend of US $0.47 per outstanding common share of its capital payable on October 15, 2026 to shareholders of record at the close of business on September 30, 2026.

ABOUT TFI INTERNATIONAL
TFI International Inc. is a North American leader in the transportation and logistics industry, operating across the United States, Canada and Mexico through its subsidiaries. TFI International creates value for shareholders by identifying strategic acquisitions and managing a growing network of wholly-owned operating subsidiaries. Under the TFI International umbrella, companies benefit from financial and operational resources to build their businesses and increase their efficiency. TFI International companies service the following segments:

  • Less-Than-Truckload;
  • Truckload;
  • Logistics.

TFI International Inc. is publicly traded on the New York Stock Exchange and the Toronto Stock Exchange under the symbol TFII. For more information, visit www.tfiintl.com.

For further information:
Alain Bédard
Chairman, President and CEO
TFI International Inc.
647-729-4079
abedard@tfiintl.com

Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs

Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development

REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development.

“We are excited to have Lisa and Shiguang join us at Jasper following our merger with Kira Pharmaceuticals,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “Lisa’s experience in regulatory affairs at multiple biotech companies and the FDA, along with Shiguang’s expertise in clinical development in rare diseases in renal and metabolic disorders are key additions as we move forward with the development of vensobafusp alfa (KP104), briquilimab and KP701 across a number of immune diseases.”

Dr. Pitt brings over 25 years of experience in leading regulatory and medical affairs across both the industry and at the U.S. Food and Drug Administration (FDA). Most recently, she served as Vice President, Regulatory Affairs at Aiolos Bio prior to its acquisition by GlaxoSmithKline. Prior to that, she held regulatory affairs leadership roles at NorthSea Therapeutics, Horizon Therapeutics, and Viela Bio prior to its acquisition by Horizon Therapeutics. Dr. Pitt served as Senior Regulatory Health Project Manager at the FDA’s Center for Drug Evaluation & Research in the former Division of Gastroenterology and Inborn Errors Products, where she managed the review of Investigation New Drug (IND), New Drug Application (NDA), and Biologic License Application (BLA) submissions. Earlier in her career, she served in Regulatory Affairs roles at AstraZeneca, PAREXEL Consulting, and Novartis. She started her career in laboratory quality assurance roles at Alpharma and Cambridge Biotech. Dr. Pitt received her Pharm.D. from the University of Maryland School of Pharmacy, an M.S.J. from Seton Hall Law School, and a Bachelor degree in Biological Sciences from the University of Delaware, and completed a post-doctoral clinical pharmacy fellowship at Novartis.

Dr. Liu joins after spending over a decade of progressive leadership roles in research and development, pharmacovigilance, and clinical development at Sanofi. Most recently, he served as Clinical Lead and Senior Clinical Research Director with a focus on rare diseases in renal and metabolic disorders and leadership in late-stage clinical trials and regulatory submissions. Prior to joining the biopharmaceutical industry, Dr. Liu held several academic appointments, including Assistant Professor at The Kidney Institute at the University of Kansas Medical Center, research faculty at the Duke University School of Medicine, and Visiting Fellow at the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). Earlier in his career, he was an Associate Professor and Attending Physician at the First Affiliated Hospital of Zhengzhou University Medical School, where he also completed his residency training. Dr. Liu received his M.D. from Zhengzhou University Medical School as well as an M.S. in Medicine and a Ph.D. in Cell Biology from the Chinese Academy of Medical Sciences and Peking Union Medical College.

Material Inducement Grants
Jasper also announced that on September 14, 2026, it granted three new employees options to purchase an aggregate of 243,000 shares of voting common stock (the “Options”) as material inducements to each employee’s employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, which was approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and amended and restated on June 2, 2023. The exercise price of each Option is $0.6328. Each Option will vest over four years, with 25% of the total number of shares vesting on the one-year anniversary of the date of commencement of such employee’s employment with Jasper and 1/48th of the total number of shares subject to each Option vesting monthly thereafter, subject in each case to such employee’s continued service to Jasper on each vesting date.

About Jasper
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. Jasper is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Contacts:
Alex Gray (investors)
Jasper Therapeutics
650-549-1454 
agray@jaspertx.com

Argot Partners (investors and media)
kira@argotpartners.com

-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year

-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma

-Early clinical observations demonstrate in vivo CAR-T generation and expansion at the current highest evaluable dose, with an initial safety profile supporting continued dose escalation

-Additional pipeline candidates would expand Tempest’s immune reset portfolio across hematologic malignancies and autoimmune diseases

BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that it has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”).

The agreement provides Tempest with an exclusive option to license Senlang’s CD7-targeted lentiviral vector platform and a portfolio of in vivo CAR-T product candidates. The portfolio includes a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate currently in Phase 1 dose escalation for relapsed/refractory multiple myeloma, as well as additional candidates for hematologic malignancies and autoimmune diseases.

“This agreement represents an important step in building Tempest as a multi-platform in vivo CAR-T company focused on immune reset for oncology and autoimmune indications,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. “Upon exercise of the option, the CD7-targeted lentiviral platform would complement our targeted LNP platform, providing two distinct approaches to generating CAR-T cells directly within patients. The lead program is currently in clinical development and has demonstrated in vivo CAR-T generation and expansion, providing encouraging early clinical support.”

Senlang’s proprietary platform uses targeted lentiviral vectors to deliver CAR transgenes to endogenous CD7-positive T cells and natural killer cells, generating CAR-T and CAR-NK cells directly within the patient. The approach is designed to avoid the individualized cell collection and external manufacturing required for conventional autologous CAR-T therapy. The lead program encodes a dual-targeting CAR directed against BCMA and GPRC5D, two clinically validated targets in multiple myeloma. Targeting both antigens may broaden malignant plasma-cell coverage and reduce the potential for tumor escape associated with the loss or downregulation of a single antigen.

The candidate is currently being evaluated in an ongoing Phase 1 dose-escalation study in patients with relapsed/refractory multiple myeloma. Early clinical observations at the current highest evaluable dose demonstrate successful generation and expansion of CAR-T cells in vivo. As of August 25, 2026, no Grade 3 or higher cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome were observed. The initial safety profile supports continued dose escalation, and patient enrollment and follow-up remain ongoing.

“Together, our targeted LNP and targeted lentiviral vector platforms are intended to support a broad portfolio of immune reset therapies,” said Dr. Angel. “The LNP platform offers a potentially repeatable approach to transient CAR expression, while the lentiviral platform is designed to support durable CAR-cell generation. These complementary capabilities provide Tempest with the flexibility to match the delivery approach to the biology and treatment requirements of different cancers and autoimmune diseases.”

Tempest and Senlang will continue to evaluate the Phase 1 results and the broader product portfolio during the option period. Tempest expects to provide additional information regarding the program as the clinical data mature.

About Senlang’s CD-7-Directed Lentiviral Platform

Senlang has a pipeline of in vivo CAR-T cell programs utilizing its CD7-directed lentiviral platform, which is designed to selectively deliver CAR payloads to endogenous CD7-positive T cells and NK cells, enabling in vivo generation of antigen-directed CAR immune cells. Proprietary nanobody-based retargeting promotes selective cell engagement and efficient transduction, while an engineered detargeted cocal envelope is intended to improve serum resistance, particle stability, and functional delivery in the bloodstream. Producer-cell engineering adds an immune-shielding feature to the lentiviral delivery particles, helping them remain functional longer in the bloodstream and improving delivery to CD7-positive immune cells. In preclinical studies, the platform demonstrated enhanced transduction in whole blood and resting PBMCs, and a single low-dose administration produced efficient in vivo transduction, rapid CAR-cell expansion, tumor-site enrichment, and durable tumor regression in mouse models.

About Tempest Therapeutics

Tempest is a clinical-stage biotechnology company developing next-generation in vivo CAR-T therapies for cancer and autoimmune disease. Tempest’s lead product candidate, TPST-4003, combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery system to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at https://www.tempesttx.com.

About Hebei Senlang Biotechnology

Hebei Senlang Biotechnology Co., Ltd., is a clinical-stage cell therapy company focused on next-generation CAR-T technologies, with specialized expertise in CD7-targeted CAR-T development. Senlang has established end-to-end capabilities spanning CAR design, vector and plasmid development, GMP manufacturing and clinical trial execution, and is currently advancing multiple CD7 CAR-T programs, including a pivotal CD7 CAR-T clinical trial for relapsed or refractory T-cell lymphoblastic lymphoma/leukemia (“T-LBL/ALL”).

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest, as well as assumptions made by, and information currently available to, management of Tempest. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: Tempest’s exclusive option with Senlang and the advancement, development, design and potential benefits of a BCMA/GPRC5D dual-targeting in vivo CAR-T therapy; the Phase 1 dose escalation trial, including the expected patient population, indications, number of patients, and expected assessments; the potential negotiation and entry into a definitive license agreement with Senlang; the potential ability of BCMA/GPRC5D dual-targeting in vivo CAR-T therapy to enable broad tumor-antigen coverage, strengthen target-cell recognition, and support durable responses; the potential applicability of Tempest’s platform and product candidates across autoimmune and oncology indications; and Tempest’s ability to achieve its operational plans. All forward-looking statements in this press release are based on Tempest’s current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest’s need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents filed by Tempest from time to time with the SEC. Except as required by applicable law, Tempest undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest’s views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest.

Investor Contacts:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

CALGARY, Alberta, Sept. 15, 2026 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold) (TSX: FRU) announces that its Board of Directors has declared a dividend of Cdn. $0.09 per common share to be paid on October 15, 2026 to shareholders of record on September 29, 2026.

These dividends are designated as “eligible dividends” for Canadian income tax purposes.

Freehold is uniquely positioned as a leading North American energy royalty company with approximately 6.0 million gross acres in Canada and approximately 1.2 million gross drilling acres in the United States. Freehold’s common shares trade on the Toronto Stock Exchange in Canada under the symbol FRU.

For further information contact

Freehold Royalties Ltd.
Todd McBride, CPA, CMA
Investor Relations
t. 403.221.0833
e. tmcbride@freeholdroyalties.com

Southfield, Michigan, Sept. 15, 2026 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that we extended the date on which our $500.0 million revolving secured warehouse facility (the “Facility”) will cease to revolve from September 20, 2027 to September 15, 2028. The interest rate on borrowings under the Facility has been decreased from the Secured Overnight Financing Rate (“SOFR”) plus 185 basis points to SOFR plus 175 basis points.

There were no other material changes to the Facility. As of September 15, 2026, we had $180.0 million outstanding under the Facility.

Additionally, we announced today that we have extended the $500.0 million asset-backed non-recourse secured financing that we entered into on August 28, 2019 (the “Financing”) and to which we refer as Term ABS 2019-2. Under the amendment effecting the extension, the date on which the Financing will cease to revolve has been extended from September 15, 2026 to September 15, 2028. The amendment also increased the interest rate under the Financing from 5.43% to 5.83%.

There were no other material changes to the terms of the Financing.

Description of Credit Acceptance Corporation

We make vehicle ownership possible by providing innovative financing solutions that enable automobile dealers to sell vehicles to consumers regardless of their credit history. Our financing programs are offered through a nationwide network of automobile dealers who benefit from sales of vehicles to consumers who otherwise could not obtain financing; from repeat and referral sales generated by these same customers; and from sales to customers responding to advertisements for our financing programs, but who actually end up qualifying for traditional financing.  

Without our financing programs, consumers are often unable to purchase vehicles, or they purchase unreliable ones. Further, as we report to the three national credit reporting agencies, an important ancillary benefit of our programs is that we provide consumers with an opportunity to improve their lives by improving their credit score and move on to more traditional sources of financing. Credit Acceptance is publicly traded on the Nasdaq Stock Market under the symbol CACC. For more information, visit creditacceptance.com.

CONTACT: Investor Relations: Jay Brinkley
Senior Vice President & Treasurer
(248) 353-2700 Ext. 6739
IR@creditacceptance.com

Beijing, Sept. 15, 2026 (GLOBE NEWSWIRE) — Wah Fu Education Group (NASDAQ: WAFU), “Wah Fu Education” or the “Company”, a Nasdaq‑listed education enterprise, today announced that the Wah Fu Education AI Ecosystem Intelligent Agent Industrialization Project, submitted by its majority‑owned subsidiary Hangzhou Wah Fu Qizhen Digital Intelligence Technology Co., Ltd., has successfully passed the review for the 2026 third batch of innovation‑and‑entrepreneurship projects in Yuhang District, Hangzhou. Selected projects will be eligible to apply for local AI technology subsidies and industrial resource support. According to relevant policies, subsidies of up to 1.1 million USD are available, subject to final official approval. The Company’s industrialization roadmap for AI‑agent technology has gained recognition under local science‑and‑innovation policies, creating favorable policy conditions for subsequent R&D implementation, scenario expansion, and industrial resource alignment of the project.

It is reported that the Yuhang District innovation‑and‑entrepreneurship project review focuses on cutting‑edge tracks including artificial intelligence and the digital economy. A comprehensive multi‑dimensional assessment is conducted covering the project’s core independent intellectual property rights, technological barriers, business model, market prospects and team strength, so as to select high‑quality innovation‑and‑entrepreneurship projects. Selected projects will qualify for corresponding financial subsidies and industrial resource support. The Wah Fu Education AI Ecosystem Intelligent Agent Industrialization Project selected in these round builds upon an industry‑leading general‑purpose large‑model technology base. It focuses on AI application development for core scenarios including educational digitalization and AI‑powered enablement for the education sector, aiming to build a scalable, reusable product system and solution suite for educational AI agents.

Dr. Yu Yang, CEO of Wah Fu Education Group, stated: “Passing this review is a recognition of Wah Fu Education’s AI technical strength. Going forward, we will take this as an opportunity to expand its footprint in business areas such as adult education and digital training. We will continue to advance technical iterations for AI‑agent applications, and provide strong impetus for the translation of AI‑agent technical achievements and commercial roll‑out.”

Since its establishment in 1999, Wah Fu Education Group has been committed to delivering diversified and customized educational solutions for students, institutions and universities. The Group keeps innovating in fields such as self‑taught higher‑education examinations, informatization of continuing education, and non‑degree training. Leveraging information technologies including artificial intelligence and big data, it has developed a new smart‑education model and grown into one of China’s influential adult distance‑education brands.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are not statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; government regulations; and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company:

Raincy Du

ir@edu-edu.com.cn

Customer Service Hotline: 400-610-0480

Website: www.edu-edu.com

Address: Room 207, Hesheng Fortune Plaza, No. 13 Deshengmenwai Street, Xicheng District, Beijing, P.R. China 100035

Agreement provides a capital-efficient, scalable framework to expand the Telesat Lightspeed ground segment worldwide

PARIS, Sept. 15, 2026 (GLOBE NEWSWIRE) — Telesat LEO ULC, a subsidiary of Telesat Corporation (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, and SatPort Infrastructure, a leading carrier-neutral ground infrastructure platform provider backed by global investment firm EQT, announced today a global build-to-suit Master Services Agreement (MSA) to develop, build and host certain landing stations to support the Telesat Lightspeed constellation.

Telesat Lightspeed is an advanced low Earth orbit (LEO) satellite network being designed to deliver secure, high-capacity, fiber-like broadband connectivity worldwide. Under the MSA, SatPort, which specializes in build-to-suit teleport and gateway solutions for LEO, MEO and GEO constellations, will deliver ground infrastructure that connects the Telesat Lightspeed constellation to the world’s terrestrial networks.

The agreement gives Telesat a capital-efficient, rapidly scalable path to expand its ground segment worldwide, and establishes SatPort as a non-exclusive strategic partner for one of the most advanced enterprise- and defence-grade LEO networks. The MSA is a framework agreement for how SatPort can provide multiple landing stations across the globe that are built to Telesat’s design specs, converting ground-segment capital expenditure into predictable operating costs.

SatPort’s build-to-suit model is designed to meet the sovereign and in-country data-landing requirements that increasingly govern satellite connectivity while ensuring Telesat retains ownership, control and operations of all network elements.

“Telesat Lightspeed is exactly the kind of mission-critical network SatPort was built to serve. By delivering ground infrastructure to a common standard, anywhere in the world, Telesat achieves capital efficiency and a scalable framework for deploying ground infrastructure,” said Joe Spytek, Chief Executive Officer, SatPort Infrastructure. “This is a landmark moment for how ground segment will be built in the LEO era – multi-tenant, carrier-neutral, and capital-efficient. SatPort is singularly focused on delivering safe, reliable, and scalable ground infrastructure, so satellite operators can trust their mission-critical terrestrial expansions to dedicated experts and focus entirely on space.”

“A globally distributed landing station network is essential to delivering the low-latency, secure connectivity our enterprise and government customers expect from Telesat Lightspeed,” said Asit Tandon, Telesat’s Chief Network and Information Officer. “SatPort’s build-to-suit hosting model, backed by stringent service level commitments that are aligned with our resiliency requirements, gives us the agility to rapidly deploy new sites as needed to meet customer demand and address evolving regulatory or sovereignty requirements.”

Guggenheim Securities acted as sole financial adviser to Telesat.

Media Contacts:

Alessandro Carani for SatPort Infrastructure
contact@satport.com

Monique Scotti for Telesat
pr@telesat.com

W2 communications for Telesat
Telesat@w2comm.com

About SatPort Infrastructure:

SatPort Infrastructure is the world’s leading carrier-neutral satellite ground infrastructure platform, purpose-built to support the next generation of satellite operators. Backed by long-term capital from global investment organization EQT Infrastructure, SatPort delivers build-to-suit teleport and gateway solutions for LEO, MEO, and GEO constellations. We combine deep operational expertise with the financial strength to fund, develop, and scale mission-critical infrastructure globally. Our model enables customers to lock in predictable operating costs across the full asset lifecycle, eliminating capital burden and operational complexity. Orbitally agnostic and globally distributed, SatPort provides secure, resilient, and strategically located infrastructure, allowing operators to focus on space while we power their ground networks. For more information visit satport.com.

About Telesat:

Telesat Corporation (Nasdaq and TSX: TSAT) (“Telesat”) is a global satellite operator and leader in advanced satellite communications, redefining broadband connectivity through its Telesat Lightspeed Low Earth Orbit (LEO) network.

Designed from inception for interoperability with enterprise and government applications, Telesat Lightspeed delivers secure, resilient, high-performance broadband connectivity with fibre-like speeds. Its advanced, software-defined architecture operates in both commercial and military Ka-band spectrum, enabling mission-critical communications with enhanced security and protection against evolving threats. Purpose-built to meet the most demanding requirements, Telesat Lightspeed provides telecom, enterprise, aviation, maritime and defence customers with unprecedented flexibility and control to dynamically manage their own services and deliver differentiated, end-to-end connectivity solutions worldwide.

With nearly 60 years of innovation, engineering excellence and a collaborative approach to customer success, Telesat is uniquely positioned to deliver secure, scalable and future-ready connectivity solutions that help customers solve their most complex communications challenges and achieve mission success. For updates on Telesat, follow us on LinkedIn, X, or visit www.telesat.com.

Forward-Looking Statements Safe Harbor

This news release contains statements that are not based on historical fact and are “forward-looking statements’’ and “forward looking information” within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. When used herein, statements which are not historical in nature, or which contain the words “will,” “can,” “establishes,” or similar expressions, are forward-looking statements. In addition, Telesat or its representatives have made or may make forward-looking statements, provide forward looking information, orally or in writing, which may be included in, but are not limited to, various filings made from time to time with the U.S. Securities and Exchange Commission (“SEC”) and Canadian securities regulatory authorities, and news releases or oral statements made with the approval of an authorized executive officer of Telesat. All statements made in this news release are made only as of the date set forth at the beginning of this news release. Telesat undertakes no obligation to update the statements made in this news release whether as a result of new information, future events or otherwise, except as required by applicable law.

These forward-looking statements and this forward-looking information are not guarantees of future performance, are based on Telesat’s current expectations, and are subject to a number of known and unknown risks, uncertainties, assumptions, and other factors, some of which are beyond Telesat’s control, are difficult to predict, and could cause actual results to differ materially from those expressed, forecasted or implied in the forward-looking statements and forward-looking information.

Known risks, uncertainties, and assumptions include, but are not limited to: risks associated with financial factors, including swings in the global financial markets, access to capital to construct our LEO satellite constellation, the ability to refinance Telesat GEO Inc.’s debt, the outcome of litigation related to Telesat GEO Inc.’s debt and the 62% equity distribution, volatility of securities values in an industry sector where values may be influenced by economic and other factors beyond Telesat’s control, inflation, rising or prolonged elevated interest rates, fluctuations in foreign exchange rates, and tariffs; risks associated with operating satellites and providing satellite services, including satellite construction or launch delays, launch failures, in-orbit failures, impaired satellite performance or dependence on large customers; the ability to deploy successfully an advanced global LEO satellite constellation and the timing of any such deployment; Telesat’s ability to meet the conditions for advance of the loans under the funding agreements for the constellation; technological hurdles, including Telesat’s and Telesat’s contractors’ development and deployment of the new technologies required to complete the constellation in time to meet Telesat’s schedule, or at all; the availability of services and components from Telesat’s and Telesat’s contractors’ supply chains; competition, including with other LEO systems, deployed and yet to be deployed; risks associated with domestic and foreign government regulation, including government restrictions and regulations, access to sufficient orbital spectrum to be able to deliver services effectively and access to sufficient geographic markets in which to sell those services; Telesat’s ability to develop significant commercial and operational capabilities; and the ability to expand Telesat’s existing satellite utilization.

The foregoing list of important factors is not exhaustive. Investors should review the other risk factors discussed in our filings, including Telesat Corporation’s Annual Report on Form 20-F, Quarterly Reports on Form 6-K, and other filings made with the SEC and the Canadian securities regulatory authorities at the System for Electronic Document Analysis and Retrieval+ (“SEDAR+”), which may be accessed on the SEC’s website at www.sec.gov and SEDAR+’s website at www.sedarplus.ca.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.